Flopropione, a Cysteine Conjugate β-Lyase 1 Inhibitor, for Prevention of Cisplatin-Induced Nephrotoxicity: Protocol for a Randomized, Open-Label, Proof-of-Concept Phase 1 and 2a Trial
JMIR Research Protocols · 2026
DOI: 10.2196/87907 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift JMIR Research Protocols, 2026. Verfasst von Takenao Koseki und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Fujita Health University Hospital, Toyoake, Aichi, Japan. Hauptthemen laut MEDLINE: Cisplatin, Cyclohexanones, Kidney Diseases. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Cisplatin-induced nephrotoxicity (CIN) is a major dose-limiting adverse event that can lead to both acute and chronic kidney injury. The formation of thiol-cisplatin conjugates within renal tubular cells has been implicated as a key mechanism underlying CIN. Flopropione is an inhibitor of cysteine conjugate β-lyase 1, an enzyme that catalyzes the formation of the thiol-cisplatin conjugate, which might prevent CIN.
Objective
We designed a clinical trial to evaluate the safety of flopropione in patients receiving cisplatin-based chemotherapy and explore its efficacy in preventing CIN.
Methods
This is a phase 1 and 2a, single-center, randomized, open-label trial conducted in patients undergoing cisplatin therapy. Participants are randomized in a 5:2 ratio per cohort to receive either flopropione or no treatment. On the day of cisplatin administration, the flopropione group receives oral flopropione twice daily (80 mg in cohort 1, 160 mg in cohort 2, and 240 mg in cohort 3). On the following day, all cohorts receive 3 doses of 80 mg of oral flopropione. A step-up dose escalation design is adopted, progressing from cohort 1 to 3 after confirming safety at each level. The primary end point is the safety of flopropione use in combination with cisplatin; the secondary end points include changes in the levels of urinary biomarkers of nephrotoxicity such as neutrophil gelatinase-associated lipocalin, liver-type fatty acid-binding protein, and kidney injury molecule-1. Blood and urine samples are collected within 48 hours before cisplatin administration and at 24 hours, 48 hours, and 1 week after its initiation for safety and efficacy assessments.
Results
The first participant was registered in July 2024. As of January 2026, participant registration is ongoing. The final participant will complete the study by March 2026. Publication of results is expected by March 2027.
Conclusions
This study is expected to contribute to advances in preventive strategies for CIN by providing evidence that inhibition of cysteine conjugate β-lyase 1 by flopropione may attenuate CIN. Trial Registration Japan Registry of Clinical Trials jRCTs041220021; https://jrct.mhlw.go.jp/en-latest-detail/jRCTs041220021 International Registered Report Identifier (IRRID) DERR1-10.2196/87907
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Fujita Health University Hospital, Toyoake, Aichi, Japan.
- Department of Regulatory Science for Evaluation and Development of Pharmaceuticals and Devices, Graduate School of Medical Sciences, Fujita Health University, Toyoake, Aichi, Japan.
- Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
- Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
- Department of Development and Education of Clinical Research, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
- Department of Advanced Diagnostic System Development, Graduate School of Medical Sciences, Fujita Health University, Toyoake, Aichi, Japan.
ORCID-Profile: Takenao Koseki, Masashi Kondo, Hidetsugu Fujigaki, Kayoko Kikuchi, Yuko Oya, Hiroshi Kato, Tomohiro Mizuno, Naotake Tsuboi, Kenji Kawada, Yasuhiro Goto, Naozumi Hashimoto, Kazuyoshi Imaizumi, Akiko Kada, Hikaru Yabuuchi, Kuniaki Saito, Hideyuki Saya
Zitieren
APA
Koseki, T., Kondo, M., Fujigaki, H., Kikuchi, K., Oya, Y., Kato, H., Mizuno, T., Tsuboi, N., Kawada, K., Goto, Y., Hashimoto, N., Imaizumi, K., Kada, A., Yabuuchi, H., Saito, K., & Saya, H. (2026). Flopropione, a Cysteine Conjugate β-Lyase 1 Inhibitor, for Prevention of Cisplatin-Induced Nephrotoxicity: Protocol for a Randomized, Open-Label, Proof-of-Concept Phase 1 and 2a Trial. JMIR Research Protocols. https://doi.org/10.2196/87907
Vancouver
Koseki T, Kondo M, Fujigaki H, Kikuchi K, Oya Y, Kato H, et al. Flopropione, a Cysteine Conjugate β-Lyase 1 Inhibitor, for Prevention of Cisplatin-Induced Nephrotoxicity: Protocol for a Randomized, Open-Label, Proof-of-Concept Phase 1 and 2a Trial. JMIR Research Protocols. 2026. doi:10.2196/87907
BibTeX
@article{Koseki2026,
author = {Koseki, Takenao and Kondo, Masashi and Fujigaki, Hidetsugu and Kikuchi, Kayoko and Oya, Yuko and Kato, Hiroshi and Mizuno, Tomohiro and Tsuboi, Naotake and Kawada, Kenji and Goto, Yasuhiro and Hashimoto, Naozumi and Imaizumi, Kazuyoshi and Kada, Akiko and Yabuuchi, Hikaru and Saito, Kuniaki and Saya, Hideyuki},
title = {Flopropione, a Cysteine Conjugate β-Lyase 1 Inhibitor, for Prevention of Cisplatin-Induced Nephrotoxicity: Protocol for a Randomized, Open-Label, Proof-of-Concept Phase 1 and 2a Trial},
journal = {JMIR Research Protocols},
year = {2026},
doi = {10.2196/87907}
}
EUVIMED